Work

Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease

Year: 2011
Type: article
Abstract: Huntington's disease (HD) is characterized clinically by movement abnormalities (i.e. chorea), psychiatric symptoms, and cognitive deficits. Mutant Huntingtin (Htt) with expanded (>36) polyQ (glutamine) repeats causes the dysfunction and death of neurons, particularly medium spiny neurons (MSNs) that account for ∼ 90% of striatal neurons, despite an ubiquitous expression. 1 , 2 The striatal neuronal death correlates with the increment of HD severity, being about ∼ 30% in grade 0 and ∼ 95% of MSNs in grade 4 patients. 3 The mechanism underlying the striatal cell death remains elusive and no effective treatment is available for this fatal disease. Different from well-characterized apoptosis, necroptosis is an emerging alternative cell death mediated by RIP1 kinase. 4 Necrostatin-1 (Nec-1) was recently confirmed to be an allosteric RIP1 kinase inhibitor (EC 50 =0.18 μ M), 5 protective in NMDA-mediated excitotoxicity and acute pathologies including cerebral ischemia. 4 Here we explored the role of necroptosis in HD by studying Nec-1 in immortalized striatal cells and R6/2 transgenic mouse.
Language: English
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W2074154917
FWCI: 3.427
Cites: 20
Cited by: 128
Related to: 10